Abstract
The rapid increase of health-threatening infections by Gram-negative pathogens along with the emergence of multidrugresistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets. One of the promising targets in Gram-negative bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-Nacetylglucosamine deacetylase (LpxC). LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A. Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-negative bacteria. In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.
Keywords: Gram-negative bacteria, MDR, lipid A, biosynthesis, LpxC, Structure, FtsH, LpxC Inhibitors
Current Medicinal Chemistry
Title:UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents
Volume: 19 Issue: 13
Author(s): J. Zhang, L. Zhang, X. Li and W. Xu
Affiliation:
Keywords: Gram-negative bacteria, MDR, lipid A, biosynthesis, LpxC, Structure, FtsH, LpxC Inhibitors
Abstract: The rapid increase of health-threatening infections by Gram-negative pathogens along with the emergence of multidrugresistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets. One of the promising targets in Gram-negative bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-Nacetylglucosamine deacetylase (LpxC). LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A. Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-negative bacteria. In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.
Export Options
About this article
Cite this article as:
Zhang J., Zhang L., Li X. and Xu W., UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents, Current Medicinal Chemistry 2012; 19 (13) . https://dx.doi.org/10.2174/092986712800167374
DOI https://dx.doi.org/10.2174/092986712800167374 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of IL-15 Signaling in the Induction of Innate Antiviral Responses
Current Signal Transduction Therapy Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design Neuromuscular Blockade in the Optimal Management of Mechanical Ventilation of Patients with Respiratory Distress
Current Respiratory Medicine Reviews Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005
Current Topics in Medicinal Chemistry Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design <i>In Silico</i> Evaluation of Various Signal Peptides to Improve Secretion of Humulin Protein in <i>E. coli</i> Host
Current Proteomics Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential and Limitations of Intervertebral Disc Endogenous Repair
Current Stem Cell Research & Therapy Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research Chronic Pancreatitis and the Development of Pancreatic Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds